NCT00819546 2026-03-25
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT06313437 2026-03-25
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03900949 2025-10-28
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04496999 2022-10-06
HDMM
Insel Gruppe AG, University Hospital Bern
Phase 1 Terminated
NCT01282502 2018-12-12
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT01174888 2016-07-06
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01161550 2013-07-23
CLAG ATRA AML
Washington University School of Medicine
Phase 1 Completed
NCT01130662 2013-03-26
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
University of Kansas Medical Center
Phase 1 Completed